# Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

> **NCT00934466** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 15 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MK2637
- **DRUG:** Comparator: MK2637
- **DRUG:** Comparator: Placebo
- **DRUG:** Comparator: Dextromethorphan
- **DRUG:** Comparator: Dextromethorphan

## Key facts

- **NCT ID:** NCT00934466
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934466, "Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00934466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*